8-K: Centene Reports Q2 2025 Loss Amid Rising Medical Costs and Risk Adjustment Revisions

Centene Corporation announced a significant loss for the second quarter of 2025, driven by increased medical costs and a reduction in Marketplace risk adjustment revenue estimates, despite strong revenue growth.

Summary

• Centene Corporation reported a GAAP diluted loss per share of $(0.51) for the second quarter ended June 30, 2025, a significant decline from a profit of $2.16 in the comparable period of 2024.
• Adjusted diluted loss per share was $(0.16) for Q2 2025, compared to adjusted diluted earnings per share of $2.42 in Q2 2024.
• Total revenues increased to $48.742 billion in Q2 2025 from $39.836 billion in Q2 2024.
• Premium and service revenues grew 18% to $42.467 billion, primarily due to premium and membership growth in the Medicare Prescription Drug Plan (PDP) business, overall market growth in the Marketplace business, and rate increases in the Medicaid business.
• The Health Benefits Ratio (HBR) increased to 93.0% in Q2 2025 from 87.6% in Q2 2024, indicating higher medical costs.
• The increase in HBR was mainly due to a reduction in the net 2025 Marketplace risk adjustment revenue transfer estimate, increased Marketplace medical costs, higher Medicaid medical costs (behavioral health, home health, high-cost drugs), and an increase to the 2025 Medicare Advantage premium deficiency reserve.
• Selling, General and Administrative (SG&A) expense ratio improved to 7.1% in Q2 2025 from 8.0% in Q2 2024, driven by leveraging expenses over higher revenues and PDP business growth.
• Cash flow provided by operations for Q2 2025 was $1.785 billion, primarily due to improved pharmacy rebate remittance timing.
• Total Medicaid membership decreased to 12,819,700 from 13,139,900 year-over-year, primarily due to redeterminations.
• Marketplace membership significantly increased to 5,862,800 from 4,401,300 year-over-year.
• Medicare Prescription Drug Plan (PDP) membership also saw substantial growth, reaching 7,845,800 from 6,603,600 year-over-year.
• Days in Claims Payable (DCP) was 47 days at June 30, 2025, a decrease of two days from the first quarter of 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant shift from profit to loss, driven by higher medical costs and adverse risk adjustment estimates. While revenue growth and SG&A efficiency are positive, the core profitability metrics are concerning, leading to management's expressed disappointment.

Positives

• Total revenues increased to $48.742 billion in Q2 2025, up from $39.836 billion in Q2 2024, representing strong top-line growth.
• Premium and service revenues grew 18% to $42.467 billion, driven by growth in the Medicare Prescription Drug Plan (PDP) and Marketplace businesses, and Medicaid rate increases.
• The SG&A expense ratio improved to 7.1% in Q2 2025 from 8.0% in Q2 2024, reflecting effective expense leveraging over higher revenues.
• Cash flow provided by operations was strong at $1.785 billion for Q2 2025, primarily due to improved pharmacy rebate remittance timing.
• Marketplace membership significantly increased to 5,862,800 from 4,401,300 year-over-year, demonstrating strong growth in this segment.
• Medicare Prescription Drug Plan (PDP) membership grew substantially to 7,845,800 from 6,603,600 year-over-year.
• The company was recognized as one of Newsweek's America's Greatest Workplaces for the third consecutive year and named to Becker's 150 Top Places to Work in Healthcare and Newsweek's America's Greatest Workplaces for Gen Z 2025.

Negatives

• The company reported a GAAP diluted loss per share of $(0.51) for Q2 2025, a significant decline from a profit of $2.16 in Q2 2024.
• Adjusted diluted loss per share was $(0.16) for Q2 2025, a substantial reversal from a profit of $2.42 in Q2 2024.
• The Health Benefits Ratio (HBR) increased to 93.0% in Q2 2025 from 87.6% in Q2 2024, indicating a deterioration in medical cost management.
• The HBR increase was primarily driven by a reduction in the net 2025 Marketplace risk adjustment revenue transfer estimate, which negatively impacted profitability.
• Increased Marketplace medical costs contributed to the higher HBR.
• Higher medical costs in Medicaid, particularly for behavioral health, home health, and high-cost drugs, also drove the HBR increase.
• An increase to the 2025 Medicare Advantage premium deficiency reserve further impacted profitability.
• Total Medicaid membership decreased to 12,819,700 from 13,139,900 year-over-year, primarily due to redeterminations.
• The second quarter of 2024 benefited from outperformance in Marketplace risk adjustment for the 2023 benefit year, a benefit not present in Q2 2025.

Risks

• Ability to design and price products that are competitive and/or actuarially sound.
• Ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs.
• Rate cuts, insufficient rate changes, or other payment reductions or delays by government payors affecting government businesses.
• Effect of social, economic, and political conditions, geopolitical events, and state and federal policies, including funding for government-sponsored healthcare programs.
• Changes in federal or state laws or regulations, including those related to income tax reform or government healthcare programs like the ACA.
• Unanticipated increased healthcare costs, including due to changes in consumer and provider behaviors, inflation, and tariffs.
• Ability to maintain or achieve improvement in CMS Star ratings and other quality scores that could impact revenue and future growth.
• Competition for providers, broker distribution networks, contract reprocurements, and organic growth.
• Ability to adequately anticipate demand and timely provide for operational resources to maintain service level requirements.
• Ability to comply with contract terms and state and federal regulations, and effectively oversee third-party vendors.
• Disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in third-party vendor relationships.
• Impairments to real estate, investments, goodwill, and intangible assets.
• Changes in senior management, loss of key personnel, or inability to attract, hire, integrate, and retain skilled personnel.
• Membership and revenue declines or unexpected trends.
• Changes in healthcare practices, new technologies, and advances in medicine.
• Ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws.
• Changes in macroeconomic conditions, including inflation, interest rates, and volatility in the financial markets.
• Negative public perception of the company and the managed care industry.
• Uncertainty concerning government shutdowns, debt ceilings, or funding.
• Tax matters.
• Disasters, climate-related incidents, acts of war or aggression, or major epidemics.
• Changes in expected contract start dates and terms.
• Changes in provider, broker, vendor, state, federal, and other contracts, and delays in regulatory approval of contracts.
• Expiration, suspension, or termination of contracts with federal or state governments.
• Difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings, or matters.
• Challenges to contract awards.
• Cyber-attacks or other data security incidents or failure to comply with applicable privacy, data, or security laws and regulations.
• Exertion of management's time and resources, and other expenses incurred in connection with complying with contract terms and regulatory undertakings.
• Changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions.
• Losses in the investment portfolio.
• Restrictions and limitations in connection with indebtedness.
• A downgrade of corporate family rating, issuer rating, or credit rating of indebtedness.
• Availability of debt and equity financing on terms that are favorable to the company.

Future Outlook

The company will provide its 2025 earnings expectations during the upcoming conference call. Management expressed disappointment with the second quarter results but stated a clear understanding of the impacting trends and a focused urgency to restore earnings trajectory, emphasizing the staying power of Medicaid, Medicare, and the Individual Marketplace.

Management Comments

• "We are disappointed by our second quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory."
• "Despite the shifting landscape, we believe that the staying power of Medicaid, Medicare and the Individual Marketplace is as strong as it has ever been."
• "Centene has significantly fortified our platform in service of these programs over the last three years, and as we move forward, we are focused on continuing to adapt with the market to deliver meaningful value to our members, our stakeholders and our shareholders over the long term."

Industry Context

Centene's results reflect ongoing dynamics within the U.S. healthcare insurance sector, particularly the impact of Medicaid redeterminations, which are reducing traditional Medicaid enrollment across the industry. However, the strong growth in Marketplace and Medicare PDP membership indicates robust demand in these segments, potentially offsetting some Medicaid losses. The increase in medical costs, especially in behavioral health and high-cost drugs, is a broader industry trend impacting profitability for many health insurers. The reduction in Marketplace risk adjustment revenue estimates highlights the complexities and volatility of revenue recognition in the ACA marketplace.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Negatively impacted by the significant diluted loss per share and the deterioration in profitability.
• Members: The company continues to support communities through donations and volunteer hours, and expands healthcare services to underserved populations through mobile health clinics, indicating continued commitment to member well-being.
• Employees: Recognized as a 'Greatest Workplace' by Newsweek, suggesting positive employee morale and work environment.

Next Steps

• The company will host a conference call on July 25, 2025, at 8:00 a.m. ET to review the financial results and provide 2025 earnings expectations.

Key Dates

Recommendation

While Centene reported a significant loss per share and an increased Health Benefits Ratio, indicating a deterioration in profitability, the company also demonstrated strong revenue growth and improved SG&A efficiency. Management acknowledged the disappointing results and stated a clear understanding of the underlying trends, committing to an urgent focus on restoring earnings trajectory. A seasoned investor would likely hold the stock to await further details and strategic insights from the upcoming conference call, where the company is expected to provide 2025 earnings expectations and a more comprehensive plan to address the current challenges, before making a definitive buy or sell decision.

Keywords

Healthcare, Managed Care, Medicaid, Medicare, Marketplace, Health Insurance, Financial Results, Earnings, SEC Filing, 8-K, Health Benefits Ratio, Risk Adjustment, Membership, Revenue, Profitability